Sandoz Group AG/€SDZ

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sandoz Group AG

Sandoz Group AG operates in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of generic medicines and biosimilars. The company's product portfolio includes a wide range of therapeutic areas, such as antibiotics, oncology, and cardiovascular treatments. Sandoz was founded as part of a broader restructuring that involved the separation from Novartis in 2022, with a focus on enhancing the accessibility of high-quality healthcare solutions. Headquartered in Switzerland, Sandoz has a significant global presence with operations spanning across numerous countries. The company emphasizes cost-effective healthcare, leveraging a substantial manufacturing and research capacity to maintain competitive strengths in the global pharmaceutical market.

Ticker

€SDZ
Sector
Health

Primary listing

XGAT

Employees

20,000

Headquarters

Basel, Switzerland
Website
www.sandoz.com

Sandoz Group AG Metrics

BasicAdvanced
€23B
119.41
€0.45
-
€0.64
1.19%

Bulls say / Bears say

With Q1 2025 sales in line with expectations, Sandoz has delivered fourteen consecutive quarters of top-line growth and reconfirmed full-year guidance for mid-single-digit net sales growth and a ~21% core EBITDA margin, demonstrating consistent execution and management confidence (Reuters)
Sandoz filed an antitrust lawsuit against Amgen in April 2025 to dismantle patent barriers around Enbrel, aiming to accelerate Erelzi’s U.S. market launch and capture part of the $3.3 billion Enbrel franchise (Reuters)
Sandoz plans major biosimilar launches in H2 2025—Wyost/Jubbonti (denosumab) in Europe and the U.S. and Tyruko (natalizumab) in the U.S.—positioning the company to drive high-margin sales and bolster growth in its fastest-growing segment (Reuters)
North America net sales grew just 1% in Q1 2025, with biosimilars declining amid the withdrawal of Cimerli, underscoring regional volatility and reliance on legacy assets for growth (Reuters)
A 20% U.S. tariff on imports from China, implemented in March 2025 and incorporated into guidance, poses ongoing cost pressures that could compress Sandoz’s margins if tariff policy expands or supply chains are disrupted (Reuters)
A proposed EU-wide uniform list price for new medicines, if adopted, risks eroding pricing flexibility for generics and biosimilars in Sandoz’s largest market, potentially squeezing margins and limiting competitive responses (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €SDZ

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs